source
- 5 drugmakers chasing Merck and Moderna in the cancer vaccine raceFollowing their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…BioSpace · 37m ago↗ source
- After a brief storm of political headwinds, mRNA is back with strong momentumA year to the day after the Trump administration slashed $500 million in funding from mRNA-based programs, the FDA approved Moderna’s flu vaccine based on the technology. Weeks later, Moderna and M…BioSpace · 38m ago↗ source
- Akeso and Summit report survival advantage for PD-1xVEGF combo over KeytrudaAt the American Society of Clinical Oncology (ASCO) 2026 meeting, Akeso Biopharma and its partner Summit Therapeutics announced new survival results for their experimental PD‑1×VEGF bispecific anti…